These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14638652)

  • 21. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 22. [Principles of therapeutic drug monitoring].
    Widmer N; Csajka C; Werner D; Grouzmann E; Decosterd LA; Eap CB; Biollaz J; Buclin T
    Rev Med Suisse; 2008 Jul; 4(165):1644-8. PubMed ID: 18767290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
    Nelson M; Cicuttini F
    Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-inferiority trials: continued advancements in concepts and methodology (special papers for the 25th Anniversary of Statistics in Medicine 25(7)).
    D'Agostino RB; Campbell M; Greenhouse J
    Stat Med; 2006 Apr; 25(7):1097-9. PubMed ID: 16526018
    [No Abstract]   [Full Text] [Related]  

  • 28. [Therapeutic drug monitoring: clinical practice].
    Widmer N; Werner D; Grouzmann E; Eap CB; Marchetti O; Fayet A; Csajka C; Decosterd LA; Buclin T
    Rev Med Suisse; 2008 Jul; 4(165):1649-50, 1652-60. PubMed ID: 18767291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive drug licensing: an opportunity to achieve transparency and accountability?
    Wright JM
    CMAJ; 2007 Jun; 176(13):1848-9. PubMed ID: 17576984
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
    Faden LB; Milne CP
    Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
    [No Abstract]   [Full Text] [Related]  

  • 31. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach.
    Baim DS; Mehran R; Kereiakes DJ; Gross TP; Simons M; Malenka D; Kaplan AV
    Circulation; 2006 Feb; 113(6):891-7. PubMed ID: 16476863
    [No Abstract]   [Full Text] [Related]  

  • 32. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods].
    Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H
    Therapie; 1985; 40(5):307-12. PubMed ID: 4095687
    [No Abstract]   [Full Text] [Related]  

  • 33. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

  • 34. GW-1000. GW Pharmaceuticals.
    Smith PF
    Curr Opin Investig Drugs; 2004 Jul; 5(7):748-54. PubMed ID: 15298072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders.
    Lassila R; Rothschild C; De Moerloose P; Richards M; Perez R; Gajek H;
    Haemophilia; 2005 Jul; 11(4):353-9. PubMed ID: 16011587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating national drug consumption using data at different points in the pharmaceutical supply chain.
    Cook MN
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):754-7. PubMed ID: 16989003
    [No Abstract]   [Full Text] [Related]  

  • 37. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 38. International Conference on Harmonisation; evaluation of stability data; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jun; 69(110):32010-1. PubMed ID: 15185712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.